Curriculum Vitae

ASSOCIATE PROF. DR. POH MAU ERN

Associate Professor
  • Department of Medicine
    Faculty of Medicine
  • ernestpoh
  • 03-79494422

ACADEMIC QUALIFICATION

  • FRCP, (Medicine Respiratory)
    Royal College of Physicians of London, United Kingdom
  • FCCP, (Medicine Respiratory)
    American College of Chest Physicians, Usa
  • MRCP, (Internal Medicine)
    Royal College of Physicians of London, United Kingdom
  • MBBS, (Medicine and Surgery)
    Universiti Malaya (um)

ADMINISTRATIVE DUTIES

  • Coordinator
    17 Jul 2024 - 16 Jul 2026 (Department)
  • Head of Unit
    01 Jun 2025 - 01 Jun 2026 (Department)
  • Committee Members
    12 Jan 2022 - 31 Dec 2023 (Department)
  • CLINICAL COORDINATOR FOR MRCP (UK) EXAMINATION 2023
    18 Oct 2023 - 19 Oct 2023 (International)
  • Coordinator
    01 Mar 2019 - 31 Dec 2022 (Department of Medicine, Faculty of Medicine)
  • Coordinator
    30 Nov 2022 - 01 Dec 2022 (Department of Medicine, Faculty of Medicine)
  • Coordinator
    01 Jan 2013 - 31 Dec 2021 (International)

MEMBERSHIPS

  • EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO), MEMBER
    2024 to 2025 (International)
  • FELLOW OF THE ASIAN PACIFIC SOCIETY OF RESPIROLOGY , MEMBER
    Since 2021 (International)
  • FELLOW OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS (FCCP), MEMBER
    Since 2020 (International)
  • FELLOW OF THE ROYAL COLLEGE OF PHYSICIANS (FRCP) , FELLOW
    Since 2020 (International)
  • MALAYSIAN THORACIC SOCIETY LUNG CANCER SPECIAL INTEREST GROUP , COMMITTEE MEMBER
    Since 2019 (National)
  • MALAYSIAN MEDICAL ASSOCIATION, MEMBER
    Since 2018 (National)
  • INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC) , MEMBER
    Since 2017 (International)
  • NSR INTERNAL MEDICINE AND RESPIRATORY MEDICINE, MEMBER
    Since 2016 (National)
  • MALAYSIAN THORACIC SOCIETY , MEMBER
    Since 2012 (National)

AWARD AND STEWARDSHIP

  • Excellence Service Award
    2023, Universiti Malaya
  • Certificate of Excellent Service
    2022, Universiti Malaya
  • Expert Panel: Doctor in The House: The Haze and Your Health
    2019, BFM 89.9 ,  (National)
  • Certificate of Excellent Service
    2019, Universiti Malaya
  • Best Lecturer Award (clinical)
    2018, FACULTY OF MEDICINE,  (University)
  • Specialty Certificate in Respiratory Medicine (sce, Rcp & Bts UK)
    2017, Royal College of Physician (UK) & British Thoracic Society,  (International)
  • Dean's List Award
    2005, Faculty of Medicine, University of Malaya ,  (University)

PUBLICATIONS

Article in Journal
WoS
  1. Mac Aogain, Micheal; Ivan, Fransiskus Xaverius; Jaggi, Tavleen Kaur; Richardson, Hollian; Shoemark, Amelia; Narayana, Jayanth Kumar; Dicker, Alison J.; Koh, Mariko Siyue; Lee, Ken Cheah Hooi; How, Ong Thun; Poh, Mau Ern; Chin, Ka Kiat; Hou, Albert Lim Yick; Hon, Puah Ser; Low, Teck Boon; Abisheganaden, John Arputhan; Dimakou, Katerina; Digalaki, Antonia; Kosti, Chrysavgi; Gkousiou, Anna; Hansbro, Philip M.; Blasi, Francesco; Aliberti, Stefano; Chalmers, James D.; Chotirmall, Sanjay H. (2024). Airway "Resistotypes" and Clinical Outcomes in Bronchiectasis, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 210(1), 47-62. doi:10.1164/rccm.202306-1059OC
  2. Poh, Mau Ern; Balakrishnan, Sivasubramaniam; Tan, Sin Nee; Abidin, Muhammad Adil Zainal; Liam, Chong Kin; Tan, Jiunn Liang; Pang, Yong Kek; Alaga, Arvindran; Tho, Lye Mun; How, Soon Hin (2024). Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer, TRANSLATIONAL LUNG CANCER RESEARCH. 13(7), 1649-1659. doi:10.21037/tlcr-24-243
  3. Poh, Mau Ern; Chai, Chee Shee; Liam, Chong Kin; Ho, Gwo Fuang; Pang, Yong Kek; Hasbullah, Harissa Husainy; Tho, Lye Mun; Nor, Ibtisam Muhamad; Ho, Kean Fatt; Thiagarajan, Muthukkumaran; Samsudin, Azlina; Omar, Azza; Ong, Choo Khoon; Soon, Sing Yang; Tan, Sin Nee; How, Soon Hin (2024). Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?, TRANSLATIONAL LUNG CANCER RESEARCH. 13(2), 307-320. doi:10.21037/tlcr-23-691
  4. Sia, Leng Cheng; Pang, Yong-Kek; Wong, Chee-Kuan; Sivakumar, Dinesh; Chandran, Deevan Marc; Soo, Chun Ian; Ling, Shan-Yan; Poh, Mau Ern; Loh, Thian Chee; Ibrahim, Nur Husna; Munusamy, Vijayan; Tan, Jiunn Liang; Leong, Wai Ling (2024). Baseline predictors of mortality in non-idiopathic pulmonary fibrosis interstitial lung disease (Non-IPF ILD), RESPIROLOGY. 29, 28-29
  5. Soo, Chun Ian; Munusamy, Vijayan; Sia, Leng Cheng; Ong, Diana Bee-Lan; Chiew, Seow Fan; Leong, Wai Ling; Annuar, Hazwan Amzar Khairul; Ibrahim, Nur Husna; Loh, Thian Chee; Tan, Jiunn Liang; Poh, Mau Ern; Wong, Chee Kuan; Pang, Yong Kek; Liam, Chong Kin (2024). Diagnostic yield, detection of driver alterations by next-generation sequencing and safety of EBUS-guided mediastinal cryobiopsy versus needle aspiration: A retrospective comparative study, RESPIROLOGY. 29, 16-17
  6. Liam, Chong Kin; Yew, Chian Yih; Pang, Yong Kek; Wong, Chee Kuan; Poh, Mau Ern; Tan, Jiunn Liang; Soo, Chun Ian; Loh, Thian Chee; Chin, Ka Kiat; Munusamy, Vijayan; Liam, Yong Sheng; Ibrahim, Nur Husna (2023). Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers, BMC CANCER. 23(1). doi:10.1186/s12885-023-11156-y
  7. Poh, Mau Ern; How, Soon Hin; Ho, Gwo Fuang; Pang, Yong Kek; Hasbullah, Harissa H.; Tho, Lye Mun; Nor, Ibtisam Muhamad; Lim, Bee Chiu; Ho, Kean Fatt; Thiagarajan, Muthukkumaran; Samsudin, Azlina; Omar, Azza; Ong, Choo Khoon; Soon, Sing Yang; Tan, Justin Yu Kuan; Abidin, Muhammad Adil Zainal (2023). Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country, CANCER MANAGEMENT AND RESEARCH. 15, 31-41. doi:10.2147/CMAR.S393729
  8. Sia, Leng Cheng; Pang, Yong-Kek; Wong, Chee Kuan; Soo, Chun Ian; Ibrahim, Nur Husna; Munusamy, Vijayan; Loh, Thian Chee; Chin, Ka Kiat; Poh, Mau Ern; Tan, Jiunn Liang; Liam, Chong-Kin (2023). Symptomatic prolonged viral shedding in long COVID - Our experience with remdesivir, EUROPEAN RESPIRATORY JOURNAL. 62. doi:10.1183/13993003.congress-2023.PA3415
  9. Soo, Chun Ian; Munusamy, Vijayan; Sia, Leng Cheng; Ibrahim, Nur Husna; Loh, Thian Chee; Tan, Jiunn Liang; Chin, Ka Kiat; Wong, Chee Kuan; Poh, Mau Ern; Pang, Yong Kek; Liam, Chong Kin (2023). Diagnostic yield and utility of endobronchial ultrasound-guided transmediastinal cryobiopsy in pulmonary disease: Novel insights from an early retrospective single-center experience in Malaysia, RESPIROLOGY. 28, 366-367
  10. Soo, Chun Ian; Poon, Khai Vern; Ayub, Atiqah; You, Hui Wen; Tan, Cai Xian; Loh, Jia Juin Kenneth; Eng, Chai Hui Carolyn; Sia, Leng Cheng; Ibrahim, Nur Husna; Chin, Ka Kiat; Loh, Thian Chee; Munusamy, Vijayan; Poh, Mau Ern; Tan, Jun Liang; Pang, Yong Kek; Liam, Chong Kin; Wong, Chee Kuan (2023). Methyprednisolone versus dexamethasone for severe COVID-19 infection: A retrospective comparative analysis of our early experience, RESPIROLOGY. 28, 92-92
  11. Soo, Chun Ian; Sia, Leng Cheng; Munusamy, Vijayan; Ibrahim, Nur Husna; Chin, Ka Kiat; Loh, Thian Chee; Tan, Jiunn Liang; Poh, Mau Ern; Wong, Chee Kuan; Pang, Yong Kek; Liam, Chong Kin (2023). Tissue coagulum clot cellblock from EBUS-TBNA for the diagnosis of necrotic mediastinal lesions, RESPIROLOGY. 28, 369-370
  12. Soo, Chun Ian; Sia, Leng Cheng; Munusamy, Vijayan; Ibrahim, Nur Husna; Chin, Ka Kiat; Loh, Thian Chee; Tan, Juinn Liang; Low, Sook Ling; Poh, Mau Ern; Wong, Chee Kuan; Pang, Yong Kek; Liam, Chong Kin (2023). Tissue coagulum clot cellblock from EBUS-TBNA for the diagnosis of necrotic lung and mediastinal lesions., EUROPEAN RESPIRATORY JOURNAL. 62. doi:10.1183/13993003.congress-2023.PA477
  13. Thng, Kai Xian; Mac Aogain, Micheal; Ivan, Fransiskus Xaverius; Narayana, Jayanth Kumar; Jaggi, Tavleen K.; Keir, Holly R.; Koh, Mariko Siyue; Ong, Thun How; Poh, Mau Ern; Low, Teck Boon; Abisheganaden, John A.; Blasi, Francesco; Aliberti, Stefano; Chalmers, James D.; Chotirmall, Sanjay H. (2023). The plasmidome in bronchiectasis, EUROPEAN RESPIRATORY JOURNAL. 62. doi:10.1183/13993003.congress-2023.PA1106
  14. Tiew, Pei Yee; Narayana, Jayanth Kumar; Li Quek, Marilynn Swee; Ang, Yan Ying; San Ko, Fanny Wai; Poh, Mau Ern; Jaggi, Tavleen Kaur; Xu, Huiying; Thng, Kai Xian; Koh, Mariko Siyue; Tee, Augustine; Hui, David Shu Cheong; Abisheganaden, John Arputhan; Tsaneva-Atanasova, Krasimira; Chew, Fook Tim; Chotirmall, Sanjay H. (2023). Sensitisation to recombinant Aspergillus fumigatus allergens and clinical outcomes in COPD, EUROPEAN RESPIRATORY JOURNAL. 61(1). doi:10.1183/13993003.00507-2022
  15. Wong, Chee Kuan; Teh, Chui Jiun; Low, Kah Seng; Chin, Ka Kiat; Soo, Chun Ian; Liam, Chong Kin; Pang, Yong Kek; Sia, Leng Cheng; Loh, Thian Chee; Ibrahim, Nur Husna; Poh, Mau Ern; Tan, Jiunn Liang; Munusamy, Vijayan (2023). Identifying the prevalence of severe asthma in a Malaysian tertiary hospital, RESPIROLOGY. 28, 99-99
  16. How, Soon Hin; Liam, Chong Kin; Abidin, Muhammad Adil Zainal; Hasbullah, Harissa H.; Tho, Lye Mun; Ho, Gwo Fuang; Nor, Ibtisam Muhamad; Pang, Yong Kek; Ho, Kean Fatt; Thiagarajan, Muthukkumaran; Ariffin, Roziana; Samsudin, Azlina; Omar, Azza; Tan, Sin Nee; Ong, Choo Khoon; Soon, Sing Yang; Poh, Mau Ern (2022). Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia, CANCER MANAGEMENT AND RESEARCH. 14, 1995-2005. doi:10.2147/CMAR.S364713
  17. How, Soon Hin; Tho, Lye Mun; Liam, Chong Kin; Hasbullah, Harissa H.; Ho, Gwo Fuang; Nor, Ibtisam Muhammad; Poh, Mau Ern; Ho, Kean Fatt; Thiagarajan, Muthukkumaran; Samsudin, Azlina; Omar, Azza; Ong, Choo Khoon; Pang, Yong Kek; Soon, Sing Yang (2022). Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country, THORACIC CANCER. . doi:10.1111/1759-7714.14442
  18. Mac Aogain, M.; Ivan, F. Xaverius; Jaggi, T.; Keir, H. R.; Dicker, A. J.; Hou, A. Lim Yick; Poh, M. Ern; Koh, M. Siyue; How, O. Thun; Tee, A.; Low, T. Boon; Abisheganaden, J. Arputhan; Blasi, F.; Aliberti, S.; Chalmers, J. D.; Chotirmall, S. H. (2022). The antimicrobial resistome in bronchiectasis: an international multicentre study, EUROPEAN RESPIRATORY JOURNAL. 60. doi:10.1183/13993003.congress-2022.1559
  19. Narayana, J.; Tiew, P.; Ang, Y.; Quek, M.; Ko, F. W.; Lim, A.; Poh, M.; Jaggi, T.; Xu, H.; Koh, M.; Low, T.; Hassan, T.; Ong, T.; Keir, H.; Tee, A.; Abisheganaden, J.; Aliberti, S.; Blasi, F.; Chalmers, J. D.; Chew, F.; Tsaneva-Atanasova, K.; Chotirmall, S. H. (2022). Topological Data Analysis (TDA) of Allergic Sensitization in Bronchiectasis and COPD, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 205
  20. Sia, L. C.; Wong, C. K.; Ooi, N. Z. M.; Chan, W. Y.; Pang, Y.; Liam, C. K.; Soo, C. I.; Tan, J. L.; Poh, M. E.; Chin, K. K.; Loh, T. C.; Ibrahim, N. H.; Munusamy, V. (2022). Persistent respiratory failure in severe COVID-19 patients - A tertiary centre experience in Kuala Lumpur, Malaysia., EUROPEAN RESPIRATORY JOURNAL. 60. doi:10.1183/13993003.congress-2022.2671
  21. Tiew, P. Y.; Narayana, J. K.; Quek, M. S. L.; Ang, Y. Y.; Ko, F. W. S.; Poh, M. E.; Jaggi, T. K.; Xu, H.; Thng, K. X.; Koh, M. S.; Tee, A.; Abisheganaden, J. A.; Tsaneva-Atanasova, K.; Chew, F. T.; Chotirmall, S. H. (2022). Aspergillus sensitization as a treatable trait in COPD, EUROPEAN RESPIRATORY JOURNAL. 60. doi:10.1183/13993003.congress-2022.69
  22. Tiew, Pei Yee; Lim, Albert Yick Hou; Keir, Holly R.; Dicker, Alison J.; Mac Aogain, Micheal; Pang, Sze Lei; Low, Teck Boon; Hassan, Tidi Maharani; Poh, Mau Ern; Xu, Huiying; Ong, Thun How; Koh, Mariko Siyue; Abisheganaden, John Arputhan; Tee, Augustine; Chew, Fook Tim; Chalmers, James D.; Chotirmall, Sanjay H. (2022). High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap, CHEST. 161(1), 40-53. doi:10.1016/j.chest.2021.07.2165
  23. Zhang, Chuanfen; Wang, Chunmei; Yang, Zhenyu; Bai, Yuquan; Shukuya, Takehito; Poh, Mau-Ern; Ekman, Simon; Li, Jian; Xu, Yuyang; Deng, Senyi (2022). Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance, TRANSLATIONAL LUNG CANCER RESEARCH. . doi:10.21037/tlcr-22-318
  24. Mac Aogain, M., Narayana, J. K., Tiew, P. Y., Ali, N., Yong, V. F. L., Jaggi, T. K., . . . Chotirmall, S. H. (2021). Integrative microbiomics in bronchiectasis exacerbations. Nature Medicine, 27(4), 32. doi: 10.1038/s41591-021-01289-7
  25. Mac Aogain, Micheal; Ivan, Fransiskus Xaverius; Jaggi, Tavleen; Keir, Holly R.; Dicker, Alison J.; Hou, Albert Lim Yick; Poh, Mau Ern; Oriano, Martina; Koh, Mariko Siyue; How, Ong Thun; Tee, Augustine; Low, Teck Boon; Abisheganaden, John Arputhan; Aliberti, Stefano; Blasi, Francesco; Chalmers, James D.; Chotirmall, Sanjay H. (2021). The bronchiectasis 'bacteriophagome', EUROPEAN RESPIRATORY JOURNAL. 58. doi:10.1183/13993003.congress-2021.OA1306
  26. Pang, Y. K., Ismail, A. I., Chan, Y. K. F., Cheong, A., Chong, Y. M., Doshi, P., . . . Taurel, A. F. (2021). Influenza in Malaysian adult patients hospitalized with community-acquired pneumonia, acute exacerbation of chronic obstructive pulmonary disease or asthma: a multicenter, active surveillance study. Bmc Infectious Diseases, 21(1), 14. doi: 10.1186/s12879-021-06360-9
  27. Poh, M. E., Ampikaipakan, S., Liam, C. K., Chai, C. S., Ramanaidoo, D., & Mydin, H. H. (2021). Management of Asthma Exacerbations in Southeast Asian Tertiary Care. Journal of Asthma and Allergy, 14, 629-640. doi: 10.2147/jaa.s309143
  28. Tian, Y., Li, P. W., Xiao, Z. H., Zhou, J., Xue, X., Jiang, N., . . . Zhao, X. G. (2021). Triptolide inhibits epithelial-mesenchymal transition phenotype through the p70S6k/GSK3/ beta-catenin signaling pathway in taxol-resistant human lung adenocarcinoma. Translational Lung Cancer Research, 10(2), 1007-+. doi: 10.21037/tlcr-21-145
  29. Chai, C. S., Liam, C. K., Poh, M. E., Ong, D. B. L., Pang, Y. K., Cheah, P. L., . . . Alip, A. (2020). Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Cancer Management and Research, 12, 5439-5450. doi: 10.2147/cmar.s253760
  30. Liam, C. K., Liam, Y. S., Poh, M. E., & Wong, C. K. (2020). Accuracy of lung cancer staging in the multidisciplinary team setting. Translational Lung Cancer Research, 9(4), 1654-1666. doi: 10.21037/tlcr.2019.11.28
  31. Tiew, P. Y., Ko, F. W. S., Narayana, J. K., Poh, M. E., Xu, H. Y., Neo, H. Y., . . . Chotirmall, S. H. (2020). "High-Risk" Clinical and Inflammatory Clusters in COPD of Chinese Descent. Chest, 158(1), 145-156. doi: 10.1016/j.chest.2020.01.043
  32. Tiew, P. Y., San Ko, F. W., Pang, S. L., Matta, S. A., Sio, Y. Y., Poh, M. E., . . . Chotirmall, S. H. (2020). Environmental fungal sensitisation associates with poorer clinical outcomes in COPD. European Respiratory Journal, 56(2), 13. doi: 10.1183/13993003.00418-2020
  33. Poh, M. E., Liam, C. K., Mun, K. S., Chai, C. S., Wong, C. K., Tan, J. L., . . . Chin, K. K. (2019). Epithelial-to-mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy. Thoracic Cancer, 10(9), 1841-1845. doi: 10.1111/1759-7714.13156
  34. Poh, M. E., Liam, C. K., Rajadurai, P., Chai, C. S. (2018). Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. Journal of Thoracic Disease, 10(7), E560-E563. doi:10.21037/jtd.2018.06.122
  35. Poh, M. E., Ng, W. L., Liam, C. K., Ramli, N. M., Hashim, S. (2018). Bilateral pulmonary sequestrations mimicking advanced lung malignancy. Journal of Thoracic Disease, 10(9), E710-E713. doi:10.21037/jtd.2018.09.12
  36. Poh, M. E., Liam, C. K., Ng, K. P., Tan, R. X. (2014). Mycobacterium Brisbanense Species Nova Isolated From a Patient With Chronic Cavitary Lung Infection, Chest. 145(4), 858-8600012-3692.
Others
  1. Liam CK, Poh ME, Liam YS (2019). Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation. J Thorac Dis 2019; 11: S1847-S1851
  2. Chai CS, Liam CK, Poh ME et al.(2017). Epidermal growth factor receptor mutation in newly diagnosed lung adenocarcinoma. J Respir Med Lung Dis; 2(2): 1016.
  3. Liam CK, Pang YK and Poh ME. EGFR Mutations in Asian Patients with Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology. 2014; 9(9):e70-1
  4. Poh ME, Liam CK, Tan JL, et al. Acrometastasis from an epidermal- growth-factor-receptor (EGFR) mutation-positive lung adenocarcinoma. Cancer Treatment Communications. 2014; Volume 2 (Issues 2-3):21-23
  5. Liam CK, Poh ME, Pang YK et al. Advanced right lung adenocarcinoma with ipsilateral breast metastasis. Respirology Case Report. 2013; 1(1):20- 22
  6. Poh ME, Liam CK, Pang YK, et al. Endobronchial metastases from resected renal cell carcinoma causing total lung collapse. Respirology Case Report. 2013; 1(2):26-7
  7. Sim BLH, Nissapatorn V, Poh ME, et al. Toxoplasmosis: a silent opportunistic diseases in HIV/AIDS patients. Research Journal of Parasitology. 2007; 2(1):23-31
Other Publications
  1. Poh ME, Liam CK, Chai CS, Pang YK, Tan JL. Abstract ID 240 Outcome of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and first-line chemotherapy in advanced lung adenocarcinoma. Respirology 2015; 20(S3): 87-103 - Extended Abstract

RESEARCH INTEREST

  • Integrative microbiomics in Bronchiectasis (Bronchiectasis, microbiome)
  • Biomarker discovery in early detection of Lung Cancer (Lung cancer, biomarker, liquid biopsy)
  • Targeted therapy and immunotherapy in Lung Cancer (Lung cancer, targeted therapy, immunotherapy)

RESEARCH PROJECT

National
  1. 2020 - 2023, RU Geran - Fakulti Program
    Lignosus Rhinocerus Tm02? As An Immunomodulatory Agent For The Treatment Of Uncontrolled Asthma And Allergic Rhinitis: A Randomised, Double Blind, Placebo-control Study ( Principal Investigator(PI))
  2. 2020 - 2021, Hospital Taping
    One-Year Surveillance Study Of Influenza and Respiratory Syncytial Virus Infections Among Hospitalised Older Adults (>=65 Years) in Malaysia ( Co-Researcher)
Private
  1. 2023 - 2026, MiRXES Lab Pte Ltd
    BIOMARKER DISCOVERY IN LUNG CANCER - MALAYSIA ( Principal Investigator(PI))
International
  1. 2018 - 2025, Private Funding
    CACZ885T2301: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) ( Consultant)
  2. 2017 - 2022, Private Funding
    MK-3475-654 : A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1 ( Consultant)
  3. 2018 - 2021, Private Funding
    MK-7264-030: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN030) ( Consultant)
  4. 2018 - 2021, Private Funding
    HM-EMSI-301: A multi-national, randomized, multi-center, active controlled, open- label Phase III study evaluating the efficacy of olmutinib versus platinum doublet chemotherapy in patients with T790M mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on one prior epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment ( Consultant)
  5. 2018 - 2020, Private Funding
    64041575MPN2001: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Adult Subjects Infected With Human Metapneumovirus ( Consultant)
  6. 2015 - 2019, Private Funding
    Bevacizumab Biosimilar Study BI 695502-A multicentre, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin plus chemotherapy in patients with advanced Non-squamous Non-small cell lung cancer. ( Consultant)
  7. 2017 - 2019, External Grant from Nanyang Techonology University Singapore
    Define clinical, microbiological and inflammatory phenotype of Asian COPD ( Principal Investigator(PI))
  8. 2016 - 2018, Private Funding
    FLAURA (NCT 02296125)- A randomized, double-blind, phase III study comparing the effcicacy and safety of AZD9291, a novel EGFR-TKI, versus gefinitib or erlotinib in treatment-na ve patients with advanced non-small cell lung cancer and an EGFR-TKI sensitizing mutation. ( Consultant)
  9. 2016 - 2018, Private Funding
    MK3475-042/KEYNOTE-042- A randomized, open label, Phase III study of Overall Survival comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Na ve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer ( Consultant)
  10. 2016 - 2018, Private Funding
    D419AC00003: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (NEPTUNE) ( Consultant)

PAPER PRESENTED

CONFERENCE
  1. Clinical Grand Rounds: A different approach to advanced NSCLC , Asia Pacific Lung Cancer Conference , International Association for the Study of Lung Cancer  (International) (06 Nov 2014 - 08 Nov 2014)
INVITED SPEAKER
  1. Approaches in ALK positive NSCLC post Lorlatinib, Lung Cancer Symposium 2024, Lung Cancer Network Malaysia (National) (27 Apr 2024 - 27 Apr 2024)
  2. EGFR mutation positive NSCLC: Mechanistic and clinical considerations for choosing tyrosine kinase inhibitors (TKI). , International Conference on Clinical And Health Sciences 2017 , The institute of Science, Technology and Development Studies  (International) (01 Nov 2017 - 01 Nov 2017)
  3. Crizotinib as 1st line therapy in patients with ALK mutation positive NSCLC patients, Brain metastasis in ALK mutation positive NSCLC patients, Pfizer Malaysia (Others) (22 Nov 2016 - 22 Nov 2016)
  4. Ultibro Breezhaler : A proven treatment for non-exacerbating and exacerbating COPD patients, A closer look into dual-bronchodilation, Novartis Malaysia (Others) (03 Nov 2016 - 03 Nov 2016)
  5. Role of the pulmonologist in the management of lung cancer, Integrated Lung Cancer Management in a Tertiary Setting (ILLUMINATE), AstraZeneca Malaysia (National) (08 Oct 2016 - 08 Oct 2016)
  6. Impact of an Extra-fine combination on symptom control of obstructive airway disease, Small Airways in Obstructive Lung Diseases, Orient Europharma (National) (11 Aug 2016 - 11 Aug 2016)
  7. The role of Gefitnib in the management of NSCLC , Personalized medicine for NSCLC , Astra Zeneca  (University) (05 Aug 2016 - 05 Aug 2016)
  8. The role of Gefitinib in the treatment of NSCLC, Personalised medicine for Non-small cell Lung Carcinoma (NSCLC), AstraZeneca Malaysia (Others) (05 Aug 2016 - 05 Aug 2016)
  9. Poorly controlled bronchial asthma , Respiratory peer-to-peer case scientific exchange meeting , Astra Zeneca  (National) (18 May 2016 - 18 May 2016)
  10. Dual- bronchodilation : A new treatment option for COPD patients , COPD workshop , Novartis  (University) (01 Dec 2015 - 01 Dec 2015)
  11. Multidisciplinary management of EGFR mutation positive NSCLC patient , Lung cancer expert forum , Roche Malaysia  (National) (31 Oct 2015 - 31 Oct 2015)
  12. Cutaneous side effects of tyrosine kinase inhibitors , Discussions on the management of EGFR mutation positive NSCLC , Roche Malaysia  (National) (28 Jun 2014 - 28 Jun 2014)
ORAL PRESENTER
  1. Outcome of First-line Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) and First-line Chemotherapy in Advanced Lung Adenocarcinoma, 20th Congress of Asian Pacific Society of Respirology (APSR) 2015, Kuala Lumpur., Asian Pacific Society of Respirology (APSR)  (International) (03 Dec 2015 - 06 Dec 2015)
  2. Epidermal growth factor receptor mutations in squamous cell carcinoma of the lung , Asia Pacific Lung Cancer Conference , International Association for the Study of Lung Cancer  (International) (06 Nov 2014 - 08 Nov 2014)
POSTER PRESENTER
  1. A cross sectional study on endobronchial TB patients in UMMC , Annual Congress of the Malaysian Thoracic Society , Malaysian Thoracic Society  (National) (12 Jun 2014 - 14 Jun 2014)
  2. Is Obesity Hypoventilation Syndrome a manifestation of more severe Obstructive Sleep Apnoea? , Annual Congress of the Malaysian Thoracic Society , Malaysian Thoracic Society  (National) (14 Jun 2013 - 16 Jun 2013)
  3. Obstructive sleep apnoea: A Malaysian perspective , Annual Congress of the Malaysian Thoracic Society , Malaysian Thoracic Society  (National) (14 Jun 2013 - 16 Jun 2013)
  4. Effect of allergic rhinitis and it's treatment on asthma control , Annual Congress of the Malaysian Thoracic Society , Malaysian Thoracic Society  (National) (06 Jul 2012 - 08 Jul 2012)

ACADEMIC/ PROF. SERVICES

Evaluation
  1. (2024) Reviewer for Journal of Multidisciplinary Healthcare, International, (Reviewer)
  2. (2024) Reviewer for International Journal of Nanomedicine, International, (Reviewer)
  3. (2024) Reviewer for Drug Design Development and Therapy, International, (Reviewer)
  4. (2024) Reviewer for Cancer Management and Research, International, (Reviewer)
  5. (2024) Reviewer for Clinical Epidemiology, International, (Reviewer)
  6. (2024) Reviewer for Lung Cancer - Targets and Therapy, International, (Reviewer)
  7. (2023) Reviewer for Oncology Letters, International, (Reviewer)
  8. (2023) Reviewer for Biomedicines, International, (Reviewer)
  9. (2023) Reviewer for Medicina, International, (Reviewer)
  10. (2023) Reviewer for Journal of Personalized Medicine, International, (Reviewer)
  11. (2023) Internal Evaluator for 3 Minute Thesis (3mt) for Research Methodology Course (mmx7001/mvx8001), University, (Internal Evaluator)
  12. (2023) Reviewer for Journal of Clinical Medicine, International, (Reviewer)
  13. (2023) Reviewer for International Journal of Environmental Research and Public Health, International, (Reviewer)
  14. (2023) Reviewer for Cells, International, (Reviewer)
  15. (2023) Reviewer for Healthcare, International, (Reviewer)
  16. (2023) Reviewer for Advances in Respiratory Medicine, International, (Reviewer)
  17. (2023) Reviewer for Neurology Asia, International, (Reviewer)
  18. (2023) Reviewer for Cancer Management and Research, International, (Reviewer)
  19. (2023) Reviewer for Pharmacogenomics and Personalized Medicine, International, (Reviewer)
  20. (2023) Reviewer for Journal of Inflammation Research, International, (Reviewer)
  21. (2023) Reviewer for Journal of Asthma and Allergy, International, (Reviewer)
  22. (2023) Reviewer for International Journal of General Medicine, International, (Reviewer)
  23. (2022) Respiratory Exit Viva Examination December 2022 (revec), National, (Internal Examiner)
  24. (2022) Characterization of The Fatty Acid Metabolism-related Genes in Lung Adenocarcinoma to Guide Clinical Therapy, International, (Reviewer)
  25. (2022) Reviewer for Future Oncology, International, (Reviewer)
  26. (2022) Reviewer for Drug Design Developement and Therapy, International, (Reviewer)
  27. (2022) Reviewer for Life-basel, International, (Reviewer)
  28. (2022) Reviewer for Journal of Personalized Medicine, International, (Reviewer)
  29. (2022) Reviewer for Pharmacogenomics & Personalized Medicine, International, (Reviewer)
  30. (2022) Reviewer for Therapeutic Advances in Respiratory Disease, International, (Reviewer)
  31. (2022) Reviewer for Journal of Personalized Medicine, International, (Reviewer)
  32. (2022) Reviewer for Journal of Inflammation Research, International, (Reviewer)
  33. (2022) Reviewer for International Journal of General Medicine, International, (Reviewer)
  34. (2022) Reviewer for Cancer Management and Research, International, (Reviewer)
  35. (2022) Reviewer for Therapeutic Advances in Respiratory Disease, International, (Reviewer)
  36. (2022) Reviewer for Journal of Personalized Medicine, International, (Reviewer)
  37. (2022) Reviewer for Cancer Management and Research, International, (Reviewer)
  38. (2022) Reviewer for Journal of Personalized Medicine, International, (Reviewer)
  39. (2022) Reviewer for International Journal of General Medicine, International, (Reviewer)
  40. (2022) Reviewer for International Journal of General Medicine, International, (Reviewer)
  41. (2022) Reviewer for Journal of Clinical Medicine, International, (Reviewer)
  42. (2022) Reviewer for Frontiers in Medicine, International, (Reviewer)
  43. (2022) Reviewer for Therapeutic Advances in Respiratory Disease, International, (Reviewer)
  44. (2022) Reviewer for Journal of Personalized Medicine, International, (Reviewer)
  45. (2021) Reviewer for Oncotargets and Therapy, International, (Reviewer)
  46. (2021) Reviewer for Therapeutic Advances in Respiratory Disease, International, (Reviewer)
  47. (2021) Reviewer for Neurology Asia, International, (Reviewer)
  48. (2021) Reviewer for Cancer Management and Research, International, (Reviewer)
  49. (2021) Reviewer for Oncotargets and Therapy, International, (Reviewer)
  50. (2021) Reviewer for Cancer Management and Research, International, (Reviewer)
  51. (2021) Reviewer for Cancer Management and Research, International, (Reviewer)
  52. (2021) Reviewer for Discover Oncology, International, (Reviewer)
  53. (2021) Reviewer for Scientific Reports, International, (Reviewer)
  54. (2021) Reviewer for Oncotargets and Therapy, International, (Reviewer)
  55. (2021) Reviewer for Lung Cancer: Targets and Therapy, International, (Reviewer)
  56. (2021) Reviewer for International Journal of General Medicine, International, (Reviewer)
  57. (2021) Reviewer for Oncotargets and Therapy, International, (Reviewer)
  58. (2021) Reviewer for Lung Cancer: Targets and Therapy, International, (Reviewer)
  59. (2021) Reviewer for Cancer Management and Research, International, (Reviewer)
  60. (2021) Reviewer for International Medical Case Reports Journal, International, (Reviewer)
  61. (2021) Reviewer for Cancer Management and Research, International, (Reviewer)
  62. (2021) Reviewer for Cancer Management and Research, International, (Reviewer)
  63. (2021) Reviewer for Lung Cancer: Targets and Therapy, International, (Reviewer)
  64. (2021) Reviewer for Npj Primary Care Respiratory Medicine, International, (Reviewer)
  65. (2021) Reviewer for International Journal of General Medicine, International, (Reviewer)
Contribution to external organisation
  1. (2021) Deputy Group Leader for Malaysian Thoracic Society Special Interest Group for Lung Cancer, National, (Expert Advisor)
  2. (2019) Department of Medicine Coordinator for UMMP 3.2, UMMP MERDU, National
Contribution to event
  1. (2024) Chairperson, National, (Panelist/Moderator)
  2. (2024) Moderator, National, (Panelist/Moderator)
  3. (2021) Moderator: Antimicrobial Resistance in Southeast Asia and Management of Bacterial Infection in Covid, National, (Panelist/Moderator)
  4. (2021) Speaker: Managing Respiratory Disorders in The New Norm 2.0, National, (Panelist/Moderator)
  5. (2021) Speaker: Interstitial Lung Disease Masterclass, National, (Panelist/Moderator)
  6. (2021) Speaker: Introduction of Liquid Biopsies and Emerging Biomarkers for Immune Checkpoint Inhibitor Therapy, National, (Panelist/Moderator)
  7. (2021) Speaker: from Evidence to Clinical Practice: Optimizing Treatment for Egfr M+ Nsclc, National, (Panelist/Moderator)
  8. (2021) Moderator: Managing Respiratory Disorders in The New Norm, National, (Panelist/Moderator)
  9. (2021) Speaker : Influenza - a Real Threat to Older Adults Amid Covid-19, National, (Panelist/Moderator)
Media appearance
  1. (2023) Klfm 97.2 : Sembang Kl 'jaga Paru Paru Setiap Hari, Cegah Komplikasi Respiratori', National, (Interview)
Mentoring
  1. (2023) Academic Advisor Mmed (mgf190012), University, (Mentor)
  2. (2021) Academic Advisor Mmed (mgf 120028), University, (Mentor)

SUPERVISION

Postgraduate Student
Master
  1. (2013) CHARACTERISTIC AND PREVALENCE EGFR-MUTATED NSCLC-PATIENT WHO DEVELOPED RESISTANCE FIRST OR SECOND GENERATION EGFR-TKI THROUGH T790M MUTATION., VIJAYAN A/L MUNUSAMY
Under Graduate Students
  1. (2025) , Nur Husna binti Ibrahim

TEACHING

Master
  1. (2024) Master of Internal Medicine (mmed)
  2. (2023) MMED - Master of Internal Medicine
Bachelor
  1. (2024) Ummp 3.3
  2. (2024) Ummp Internal Medicine Vetting
  3. (2024) Ummp Stage 1
  4. (2024) Ummp Stage 2
  5. (2024) Ummp Stage 3.1 Cohort 2022
  6. (2019) 000 - Ummp 2
  7. (2019) 000 - Ummp 3.1
  8. (2018) 000 - Ummp 3.1
  9. (2018) 000 - Ummp Stage 1
  10. (2018) 000 - Ummp Stage 2
  11. (2018) 000 - Ummp Stage 3.1
  12. (2018) 000 - Ummp 1
  13. (2017) 000 - Ummp 1
  14. (2017) 000 - Ummp 2
  15. (2017) 000 - Ummp 3.1
  16. (2017) 000 - Ummp 3.2
  17. (2017) 000 - Ummp 3.2
  18. (2017) 000 - Ummp 3.2 Delayed Print
  19. (2017) 000 - Ummp Print
  20. (2016) 000 - MBBS Phase Iiib
  21. (2016) 000 - MBBS Phase Iiib
  22. (2016) 000 - Ummp 3.1
  23. (2015) 000 - MBBS Phase Iib
  24. (2015) 000 - Ummp 1
  25. (2015) 000 - Ummp 3.1

COURSE ATTENDED

Internal/ External Course
  1. BENGKEL TRAINING OF TRAINERS PROGRAM MMED PERUBATAN DALAMAN KURIKULUM KEBANGSAAN , PUTRAJAYA MARRIOTT HOTEL IOI RESORT CITY (28 Feb 2022 - 01 Mar 2022)
  2. ESMO ASIA CONGRESS 2024, SINGAPURA (05 Dec 2024 - 08 Dec 2024)
  3. MALAYSIAN THORACIC SOCIETY ANNUAL CONGRESS 2024 , PERSADA JOHOR INTERNATIONAL CONVENTION CENTRE (29 Aug 2024 - 31 Aug 2024)
  4. 8TH WORLD BRONCHIECTASIS CONFERENCE , BRISBANE, AUSTRALIA (13 Jul 2025 - 17 Jul 2025)